What the FDA labels say about taking them together
Danicopan and ravulizumab
Danicopan's FDA label of May 12, 2026 names ravulizumab in its warnings and precautions section; the ravulizumab label PlainMeds reads does not name danicopan.
Check it at the source: the danicopan FDA label on DailyMed (effective May 12, 2026, Alexion Pharmaceuticals Inc.); the ravulizumab FDA label on DailyMed (effective October 9, 2025).
What does the danicopan label say about ravulizumab?
Danicopan label, warnings and precautionsIf discontinuation of VOYDEYA is necessary, continue background treatment with ravulizumab or eculizumab or consider alternative therapy if necessary.
Source: FDA drug label (Voydeya), Alexion Pharmaceuticals Inc., effective May 12, 2026 (SPL set ab8d1cbd-a28b-4d49-82ab-5c7460719ac7), via openFDA; the full label on DailyMed
What does the ravulizumab label say about danicopan?
Ravulizumab's label (effective October 9, 2025) does not name danicopan in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Ultomiris), Alexion Pharmaceuticals Inc., effective October 9, 2025 (SPL set a9a590d9-0217-43c7-908d-e62a71279791), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Danicopan | Ravulizumab | |
|---|---|---|
| Labeled for | n/a | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once